EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Pharmacokinetics and Safety of Linezolid Tablets of 2 Different Manufacturers in Healthy Chinese Subjects in Fasting and Fed States

Hanjing Chen, Hongrong Xu, Fei Yuan, Hui Li, Lei Sheng, Chao Liu, Weili Chen, Xuening Li

Clinical Pharmacology in Drug Development · 2024-11 · 13 (11) · 1239-1244

DOI: 10.1002/cpdd.1462 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 19.08.2024. Verfasst von Hanjing Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Linezolid. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to evaluate the pharmacokinetics (PKs) and safety of a generic drug, linezolid, compared to those of a reference drug in healthy Chinese subjects under both fasting and fed conditions. This was a randomized, open‐label, 2‐period, 2‐sequence crossover study. The subjects received a single dose of the test or reference drug, linezolid (600 mg), in each period. The PK parameters were calculated using a non‐compartmental method and compared between the 2 drugs. Bioequivalence was analyzed using geometric mean ratios (GMRs) of the 2 formulations and their corresponding 90% confidence intervals (CIs). The safety of the 2 formulations was assessed under both fasting and fed conditions. Forty‐eight subjects completed the study, 24 each in the fasting and feeding groups. The average plasma concentration‐time patterns of linezolid were similar for both medications under both conditions. The GMR and 90% CIs of the maximum plasma concentration and the area under the plasma concentration‐time curve of linezolid were ranged from 0.80 to 1.25. Both drugs were well tolerated with a similar incidence of adverse drug reactions. In conclusion, the PK and safety profiles of the 2 formulations were comparable. Food intake did not influence the PK profiles of linezolid. These results suggest that the test drug can be used as an alternative to reference drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsLinezolidAdultFemaleHumansMaleYoung AdultArea Under CurveChinaCross-Over StudiesDrugs, GenericEast Asian PeopleFastingFood-Drug InteractionsHealthy VolunteersTabletsTherapeutic Equivalency

Stichwörter der Autor:innen

bioequivalencefood effectlinezolidpharmacokineticssafety

Substanzen

Anti-Bacterial AgentsDrugs, GenericLinezolidTablets

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, China.

Zitieren

APA

Chen, H., Xu, H., Yuan, F., Li, H., Sheng, L., Liu, C., Chen, W., & Li, X. (2024). Pharmacokinetics and Safety of Linezolid Tablets of 2 Different Manufacturers in Healthy Chinese Subjects in Fasting and Fed States. Clinical Pharmacology in Drug Development, 13(11), 1239-1244. https://doi.org/10.1002/cpdd.1462

Vancouver

Chen H, Xu H, Yuan F, Li H, Sheng L, Liu C, et al. Pharmacokinetics and Safety of Linezolid Tablets of 2 Different Manufacturers in Healthy Chinese Subjects in Fasting and Fed States. Clinical Pharmacology in Drug Development. 2024;13(11):1239-1244. doi:10.1002/cpdd.1462

BibTeX
@article{Chen2024,
  author = {Chen, Hanjing and Xu, Hongrong and Yuan, Fei and Li, Hui and Sheng, Lei and Liu, Chao and Chen, Weili and Li, Xuening},
  title = {Pharmacokinetics and Safety of Linezolid Tablets of 2 Different Manufacturers in Healthy Chinese Subjects in Fasting and Fed States},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2024},
  volume = {13},
  number = {11},
  pages = {1239--1244},
  doi = {10.1002/cpdd.1462}
}
Kostenlos starten →